CFM
MDGL icon

Catalyst Funds Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Catalyst Funds Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.28M Buy
13,561
+12,948
+2,112% +$6.63M 0.41% 59
2026
Q1 		$321K Buy
+613
New +$293K 0.05% 336
2024
Q2 		– Sell
-300
Closed -$80.1K – 1420
2024
Q1 		$80.1K Buy
+300
New +$70.7K 0.02% 452

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Catalyst Funds Management's MDGL Position: Q2 2026 in Review

Catalyst Funds Management increased its Madrigal Pharmaceuticals (MDGL) stake by 2,112% in Q2 2026, buying an estimated $6.63M and bringing the position to 13,561 shares worth $7.28M. The position accounts for 0.41% of the portfolio, ranked #59.

Catalyst Funds Management first reported a position in MDGL in Q1 2024 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Catalyst Funds Management held 13,561 shares of Madrigal Pharmaceuticals worth $7.28M as of Q2 2026.
  • Catalyst Funds Management bought 12,948 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.63M.
  • Madrigal Pharmaceuticals made up 0.41% of Catalyst Funds Management's portfolio in Q2 2026, its #59 holding.
  • Catalyst Funds Management first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.